Related Experiment Video
Updated: Mar 18, 2026
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019
NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016
David S Ettinger1, Douglas E Wood1, Wallace Akerley1
1From The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Huntsman Cancer Institute at the University of Utah; UC San Diego Moores Cancer Center; Fox Chase Cancer Center; University of Colorado Cancer Center; Roswell Park Cancer Institute; Dana-Farber/Brigham and Women's Cancer Center; Duke Cancer Institute; Moffitt Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Vanderbilt-Ingram Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Fred & Pamela Buffett Cancer Center; Massachusetts General Hospital Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Michigan Comprehensive Cancer Center; Stanford Cancer Institute; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; City of Hope Comprehensive Cancer Center; Memorial Sloan Kettering Cancer Center; Mayo Clinic Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; and National Comprehensive Cancer Network.
Recent updates to Malignant Pleural Mesothelioma (MPM) guidelines include new first-line systemic therapy options. The NCCN panel now recommends bevacizumab/cisplatin/pemetrexed for unresectable MPM patients eligible for bevacizumab.
Area of Science:
- Oncology
- Clinical Guidelines
- Thoracic Surgery
Background:
- Malignant Pleural Mesothelioma (MPM) is a rare and aggressive cancer.
- Current management strategies require frequent updates based on emerging evidence.
Framework:
- NCCN Guidelines provide evidence-based recommendations for cancer care.
- Recent insights focus on systemic therapy and surgical management of MPM.
Implementation:
- The NCCN panel recommends cisplatin/pemetrexed as a standard first-line therapy (Category 1).
- Bevacizumab/cisplatin/pemetrexed is now recommended as a first-line option for unresectable MPM patients suitable for bevacizumab.
Implications:
- These guideline updates offer expanded therapeutic options for MPM patients.
- The recommendations aim to optimize treatment decisions and improve patient outcomes in MPM management.
Related Concept Videos
01:30Pleural Disorders: Types and Brief Description
01:28Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
01:30Endoscopic Studies I: Bronchoscopy and Thoracoscopy
Bronchoscopy
Description
Bronchoscopy is a procedure that involves direct visualization of the larynx, trachea, and bronchi for diagnostic and therapeutic purposes. A flexible fiber optic or rigid bronchoscope is used to carry out the procedure. The fiber-optic bronchoscope is more frequently used due...
01:25Pleural Effusion I: Introduction
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's...
01:27Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...